Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - Diphenylpyraline is an antihistamine. Antihistamines used in the treatment of allergy act by competing with histamine for H 1-receptor sites on effector cells. Antihistamines prevent, but do not reverse, responses mediated by histamine alone. Antihistamines antagonize, in varying degrees, most of the pharmacological effects of histamine, including urticaria and pruritus. (en)
|
http://linked.open...generalReferences
| - # Lapa GB, Mathews TA, Harp J, Budygin EA, Jones SR: Diphenylpyraline, a histamine H1 receptor antagonist, has psychostimulant properties. Eur J Pharmacol. 2005 Jan 4;506(3):237-40. Epub 2004 Dec 8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15627433 # Ohno T, Kobayashi S, Hayashi M, Sakurai M, Kanazawa I: Diphenylpyraline-responsive parkinsonism in cerebrotendinous xanthomatosis: long-term follow up of three patients. J Neurol Sci. 2001 Jan 1;182(2):95-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11137513 # Puhakka H, Rantanen T, Virolainen E: Diphenylpyraline (Lergobine) in the treatment of patients suffering from allergic and vasomotor rhinitis. J Int Med Res. 1977;5(1):37-41. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14039 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...ugbank/indication
| - For use in the treatment of allergic rhinitis, hay fever, and allergic skin disorders. (en)
|
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Antihistamines such as diphenylpyraline used in the treatment of allergy act by competing with histamine for H1-receptor sites on effector cells. This reduces the effects of histamine, leading to a temporary reduction of allergy symptoms. (en)
|
http://linked.open.../drugbank/synonym
| - Diphenylpyralamine (en)
- 1-Methyl-4-hydroxypiperidine benzhydryl ether (en)
- 1-Methyl-4-piperidyl benzhydryl ether (en)
- 4-(Benzhydryloxy)-1-methylpiperidine (en)
- 4-(Benzhydryloxy)-N-methylpiperidine (en)
- Difenilpiralina (en)
- Diphenylpyralinum (en)
|
http://linked.open.../drug/hasAHFSCode
| |
http://linked.open.../drugbank/mixture
| |
http://linked.open...nk/proteinBinding
| - > 99% in human serum albumin (en)
|
http://linked.open...ogy/drugbank/salt
| |
http://linked.open...ynthesisReference
| - Knox, L.H. and Kapp, R.; U.S. Patent 2,479,843; August 23, 1949; assigned to Nopco Chemical Company. (en)
|
http://linked.open...y/mesh/hasConcept
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - Well absorbed after oral administration. (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...-strongest-basic-
| |